PFE
Pfizer Inc.
Is PFE Halal?
Pharmaceutical medicines are generally permissible, and March 2026 financial ratios pass the examined total-assets limits, while product-level formulation questions remain unresolved.
What You Should Know
Pfizer develops and sells medicines, vaccines and related biopharmaceutical products, so its core life-preserving activity remains generally permissible. Its March 29, 2026 filing shows debt at 31.04% of total assets, identifiable liquidity at 5.42%, receivables plus cash at 6.88%, and disclosed interest income at 0.80% of quarterly revenue. Product formulation, ingredient and collaboration details are not sufficient to publish a universal prohibited-revenue percentage.
⚠️ Concerns
- •Debt was 31.04% of total assets after acquisition-related financing
- •Some products or manufacturing inputs may involve porcine, animal-derived or other scholar-sensitive ingredients
- •Interest income was 0.80% of quarterly revenue
- •Product safety, pricing, access, clinical research, patents, government contracts, manufacturing and supply-chain ethics require qualitative review
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-29; calculated 2026-07-14.
64,455 / 207,618
11,257 / 207,618
14,288 / 207,618
115 / 14,451
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 31.04%, liquidity/assets is 5.42%, receivables plus cash/assets is 6.88%, and disclosed interest income is 0.80%; product-level business revenue remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
The examined total-assets ratios pass, but product formulation and business-category revenue remain undisclosed; this is not an index-membership claim.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and identifiable liquidity/assets are below the examined 33% limits; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
Pfizer develops and commercializes medicines, vaccines and biopharmaceutical products. Life-preserving healthcare activity is generally permissible, while product- and formulation-specific questions require evidence.
Limitation: The filing does not provide a universal prohibited-revenue numerator by formulation, excipient, animal-derived input, indication, contract or collaboration, so no exact percentage is claimed.
Purification
Disclosed interest income is 0.80% of quarterly revenue, but product-level screened revenue remains unavailable; no fixed purification percentage is prescribed.
Inputs, assumptions and primary sources
- Amounts are USD millions from Pfizer's March 29, 2026 Form 10-Q.
- Debt includes short-term borrowings and current long-term debt of $3,890 million plus long-term debt of $60,565 million.
- Cash is $1,703 million. Identifiable debt securities are $9,554 million of available-for-sale and held-to-maturity government, agency and corporate securities; equity investments are excluded.
- Trade accounts receivable is $12,585 million and quarterly revenue is $14,451 million.
- Disclosed interest income is $115 million for the quarter.
- Pfizer reports product, alliance and royalty revenue but does not quantify every formulation, ingredient, animal-derived input, clinical use or licensing category as a reproducible prohibited-revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →